Especially, TP53 is significantly enriched in clonal mutations in breast cancer, colon cancer and low grade glioma, which is consistent with the results that TP53 somatic mutations had a clonal advantage over other genes in breast cancer [31]. This evidence concerns the gene TP53 and malignant colon neoplasm.